Ken Griffin Aridis Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	SELL	$0.16 - $0.4 $880 - $2,200	-5,500 Reduced 22.45%	19,000 $4,000
Q1 2023 May 15, 2023	BUY	$0.31 - $1.5 $7,595 - $36,750	24,500 New	24,500 $7,000
Q3 2022 Nov 14, 2022	BUY	$0.73 - $2.47 $1,022 - $3,458	1,400 Added 13.46%	11,800 $11,000

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.